biostudies-literatureUnknown14Cho SH<h4>Aim</h4>We explored the effectiveness of continuous glucose monitoring for 1 year on glycated A1c reduction in adults with type 1 diabetes mellitus.<h4>Methods</h4>We included type 1 diabetes mellitus adults who were either new continuous glucose monitoring users (<i>N</i> = 155) or non-users who were under standard care (<i>N</i> = 384). Glycated A1c was measured at baseline and 3, 6, 9, and 12 months. Individuals with (<i>N</i> = 155) or without continuous glucose monitoring use (<i>N</i> = 310) were matched 1:2 by propensity score. We used the linear mixed models to identify the quantitative reduction in repeated measures of glycated A1c.<h4>Results</h4>The change in glycated A1c from baseline to 12 months was -0.5% ± 1.0% for the continuous glucose monitoring user group (<i>N</i> = 155, <i>P</i> < 0.001) and -0.01% ± 1.0% for the non-user group (<i>N</i> = 310, <i>P</i> = 0.816), with a significant difference between the two groups (<i>P</i> = 0.003). Changes in glycated A1c were significant at 3, 6, 9, and 12 months compared with those at baseline in patients using continuous glucose monitoring (<i>P</i> < 0.001), and the changes differed significantly between the groups (<i>P</i> < 0.001). A linear mixed model showed an adjusted treatment group difference in mean reduction in glycated A1c of -0.11% (95% confidence interval, -0.16 to -0.06) each three months. In the continuous glucose monitoring user group, those who achieved more than 70% of time in range significantly increased from 3 months (37.4%) to 12 months (48.2%) (<i>P</i> < 0.001).<h4>Conclusion</h4>In this longitudinal study of type 1 diabetes mellitus adults, the use of continuous glucose monitoring for 1 year showed a significant reduction in glycated A1c in real-world practice.Frontiers in endocrinology1165471https://www.ebi.ac.uk/biostudies/studies/S-EPMC10225713biostudies-literatureImpact of continuous glucose monitoring on glycemic control and its derived metrics in type 1 diabetes: a longitudinal study.PMC10225713Kim SLee YBKim GHur KYCho SHKim JHJin SMfalseImpact of continuous glucose monitoring on glycemic control and its derived metrics in type 1 diabetes: a longitudinal study.<h4>Aim</h4>We explored the effectiveness of continuous glucose monitoring for 1 year on glycated A1c reduction in adults with type 1 diabetes mellitus.<h4>Methods</h4>We included type 1 diabetes mellitus adults who were either new continuous glucose monitoring users (<i>N</i> = 155) or non-users who were under standard care (<i>N</i> = 384). Glycated A1c was measured at baseline and 3, 6, 9, and 12 months. Individuals with (<i>N</i> = 155) or without continuous glucose monitoring use (<i>N</i> = 310) were matched 1:2 by propensity score. We used the linear mixed models to identify the quantitative reduction in repeated measures of glycated A1c.<h4>Results</h4>The change in glycated A1c from baseline to 12 months was -0.5% ± 1.0% for the continuous glucose monitoring user group (<i>N</i> = 155, <i>P</i> < 0.001) and -0.01% ± 1.0% for the non-user group (<i>N</i> = 310, <i>P</i> = 0.816), with a significant difference between the two groups (<i>P</i> = 0.003). Changes in glycated A1c were significant at 3, 6, 9, and 12 months compared with those at baseline in patients using continuous glucose monitoring (<i>P</i> < 0.001), and the changes differed significantly between the groups (<i>P</i> < 0.001). A linear mixed model showed an adjusted treatment group difference in mean reduction in glycated A1c of -0.11% (95% confidence interval, -0.16 to -0.06) each three months. In the continuous glucose monitoring user group, those who achieved more than 70% of time in range significantly increased from 3 months (37.4%) to 12 months (48.2%) (<i>P</i> < 0.001).<h4>Conclusion</h4>In this longitudinal study of type 1 diabetes mellitus adults, the use of continuous glucose monitoring for 1 year showed a significant reduction in glycated A1c in real-world practice.2023-01-01T00:00:00Z20232025-05-18T12:53:33.12Z2025-05-18T12:53:33.12ZS-EPMC102257133725597310.3389/fendo.2023.1165471